Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Advances in prostate cancer.

Charles J Ryan1, Eric J Small

  • 1Urologic Oncology Program, UCSF Comprehensive Cancer Center, University of California-San Francisco, San Francisco, California 94143, USA. ryan@medicine.ucsf.edu

Current Opinion in Oncology
|April 8, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Plasma extracellular vesicle proteomics nominates candidate biomarkers of <sup>177</sup>Lu-PSMA-617 outcomes in metastatic prostate cancer patients.

Cell reports. Medicine·2026
Same author

Carboplatin, Cabazitaxel, and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase II Study.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Clinical Utility of Transcriptomic Signatures to Identify Androgen Receptor and Neuroendocrine Signaling in Prostate Cancer.

JCO precision oncology·2026
Same author

Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Evolving strategies in prostate cancer: Emerging approaches and unmet needs from the Bridging the Gaps in Prostate Cancer expert panel.

Cancer·2026
Same author

Evolution of AR and Non-AR Alterations in ctDNA of Patients with Metastatic Prostate Cancer Treated in the Phase III Alliance A031201 Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Artificial intelligence-augmented robotic surgery in gynecologic oncology: intraoperative assistance and analytics.

Current opinion in oncology·2026
Same journal

Artificial intelligence in cervical cancer screening and triage: a role-stratified systematic review and bivariate meta-analysis.

Current opinion in oncology·2026
Same journal

Deep learning assisting the surgical management of gynecologic cancers.

Current opinion in oncology·2026
Same journal

Pain management in pancreatic cancer: time to change our strategy!

Current opinion in oncology·2026
Same journal

Systemic radionuclide treatments in gastro-entero-pancreatic neuroendocrine tumours.

Current opinion in oncology·2026
Same journal

5-Fluorouracil at seventy: still attractive but barely understood. A cautionary tale for drug development.

Current opinion in oncology·2026
See all related articles

Recent prostate cancer research offers new diagnostic and management insights. Lowering the prostate-specific antigen threshold may increase early detection, while new treatments show promise for localized and advanced disease.

Area of Science:

  • Urology
  • Oncology
  • Medical Research

Background:

  • Prostate cancer remains a significant health concern globally.
  • Continuous advancements in understanding and treating prostate cancer are crucial.

Purpose of the Study:

  • To review key developments in prostate cancer diagnosis, prevention, and management from the past year's medical literature.
  • To inform clinicians about significant findings impacting patient care.

Main Methods:

  • Literature review of recently published medical research on prostate cancer.
  • Analysis of studies focusing on diagnostic thresholds, therapeutic interventions, and genetic factors.

Main Results:

  • Lowering the serum prostate-specific antigen (PSA) threshold to 2.5 ng/mL could double prostate cancer diagnosis rates in young men.

Related Experiment Videos

  • Oral finasteride reduces overall incidence but may increase high-grade tumors; androgen receptor gene mutations are less common than previously thought.
  • Four months of androgen deprivation with whole pelvis radiotherapy benefits high-risk localized prostate cancer; chemotherapy and bisphosphonates show refined clinical benefits.

    • Conclusions:

    • Findings have broad implications for primary care physicians and specialists managing prostate cancer.
    • Several recent developments are expected to significantly alter current treatment paradigms for prostate cancer.